Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Equity: 2014-2025

Historic Return on Equity for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to 0.10%.

  • Theravance Biopharma's Return on Equity rose 36.00% to 0.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.10%, marking a year-over-year increase of 36.00%. This contributed to the annual value of -0.33% for FY2024, which is 16.00% down from last year.
  • As of Q3 2025, Theravance Biopharma's Return on Equity stood at 0.10%, which was up 238.83% from 0.03% recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Return on Equity peaked at 15.09% during Q3 2022, and registered a low of -0.39% during Q1 2025.
  • Over the past 3 years, Theravance Biopharma's median Return on Equity value was -0.21% (recorded in 2024), while the average stood at 0.30%.
  • As far as peak fluctuations go, Theravance Biopharma's Return on Equity soared by 1,498bps in 2022, and later slumped by 1,526bps in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Return on Equity stood at -0.20% in 2021, then soared by 229bps to 2.09% in 2022, then plummeted by 233bps to -0.24% in 2023, then declined by 11bps to -0.35% in 2024, then surged by 36bps to 0.10% in 2025.
  • Its Return on Equity stands at 0.10% for Q3 2025, versus 0.03% for Q2 2025 and -0.39% for Q1 2025.